HLA-C and neoplasm: The bispecific T-cell engager (BiTE) antibodies are fusion proteins consisting of two single-chain variable fragments of different antibodies, one specific to a tumor-cell antigen and the other a T-cell receptor, usually CD3, which promotes T-cell cytotoxic activity against the tumor cell independent from MHC and co-stimulatory pathways.